Research Analysts Set Expectations for NTLA FY2030 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Brookline Capital Management issued their FY2030 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Tuesday, January 27th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $75.05 for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. Intellia Therapeutics’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.34) earnings per share.

A number of other equities analysts have also commented on NTLA. Evercore ISI set a $8.00 price objective on Intellia Therapeutics and gave the stock an “in-line” rating in a research note on Tuesday, November 11th. Bank of America dropped their price target on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Jones Trading lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 11th. HC Wainwright lifted their target price on shares of Intellia Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, JMP Securities cut their price target on shares of Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating on the stock in a research report on Tuesday, October 28th. Nine equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $18.00.

Intellia Therapeutics Trading Down 6.8%

NASDAQ NTLA opened at $13.82 on Wednesday. The firm has a market capitalization of $1.60 billion, a PE ratio of -3.24 and a beta of 2.05. The business’s 50-day moving average price is $10.23 and its two-hundred day moving average price is $12.94. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the sale, the chief executive officer directly owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,051 shares of company stock valued at $488,600 over the last ninety days. 3.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NTLA. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics in the third quarter valued at approximately $30,000. Blue Bell Private Wealth Management LLC bought a new position in shares of Intellia Therapeutics in the 3rd quarter worth $30,000. Advisory Services Network LLC acquired a new stake in Intellia Therapeutics in the 3rd quarter valued at $33,000. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at $26,000. Finally, Danske Bank A S bought a new stake in Intellia Therapeutics during the 3rd quarter valued at $50,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.